Carbobenzoxy-5,5,5-trifluor-DL-leucin | 69896-60-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Carbobenzoxy-5,5,5-trifluor-DL-leucin
• 英文别名: 5,5,5-Trifluoro-4-methyl-2-(phenylmethoxycarbonylamino)pentanoic acid
• CAS: 69896-60-2
• 化学式: C₁₄H₁₆F₃NO₄
• 分子量: 319.281
• InChiKey: WKKAABMAKGDZGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  氨基乙腈盐酸盐 、 Carbobenzoxy-5,5,5-trifluor-DL-leucin 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 benzyl N-[1-(cyanomethylamino)-5,5,5-trifluoro-4-methyl-1-oxopentan-2-yl]carbamate
  参考文献：
  名称：

  Design and Synthesis of Tri-Ring P₃ Benzamide-Containing Aminonitriles as Potent, Selective, Orally Effective Inhibitors of Cathepsin K

  摘要：

  We have prepared a series of achiral aminoacetonitriles, bearing tri-ring benzamide moieties and an aminocyclohexanecarboxylate residue at P-2. This combination of binding elements resulted in sub-250 pM, reversible, selective, and orally bioavailable cathepsin K inhibitors. Lead compounds displayed single digit nanomolar inhibition in vitro (of rabbit osteoclast-mediated degradation of bovine bone). The best compound in this series, 39n (CRA-013783/ L-006235), was orally bioavailable in rats, with a terminal half-life of over 3 h. 39n was dosed orally in ovariectomized rhesus monkeys once per day for 7 days. Collagen breakdown products were reduced by up to 76% dose-dependently. Plasma concentrations of 39n above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. Inhibition of collagen breakdown by cathepsin K inhibitors suggests this mechanism of action may be useful in osteoporosis and other indications involving bone resorption.

  DOI：

  10.1021/jm058198r

文献信息

• MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US20170114080A1

  公开（公告）日：2017-04-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用相同的方法。
• [EN] MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF<br/>[FR] MODULATEURS DE L'INTERACTION SESTRINE-GATOR2 ET UTILISATIONS DE CES DERNIERS
  申请人：NAVITOR PHARM INC

  公开号：WO2018200625A1

  公开（公告）日：2018-11-01

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用相同的方法。
• Modulators of sestrin-GATOR2 interaction and uses thereof
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US10100066B2

  公开（公告）日：2018-10-16

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• Modulators of Sestrin-GATOR2 interaction and uses thereof
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US10752644B2

  公开（公告）日：2020-08-25

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• [EN] MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF<br/>[FR] MODULATEURS D'INTERACTION SESTRINE-GATOR2 ET LEURS UTILISATIONS
  申请人：NAVITOR PHARM INC

  公开号：WO2017070518A1

  公开（公告）日：2017-04-27

  The present invention provides compounds, compositions thereof, and methods of using the same.